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Abstract
Background: Liver injury and regeneration involve complicated processes and are affected by various physio-
pathological conditions. Surgically, severe liver injury after surgical resection often leads to fatal liver failure,
especially with some underlying pathological conditions such as steatosis. Therefore, protection from the injury
of hepatocytes and liver is a serious concern in various clinical settings.
Methods: We studied the effects of the farnesoid X receptor (FXR) on cell survival and steatosis in mouse
hepatocytes (AML12 mouse liver cells) and investigated their molecular mechanisms. We next studied whether
or not FXR improves liver injury, regeneration and steatosis in a mouse model of partial hepatectomy (PH) with
steatosis.
Results: An FXR-specific agonist, GW4064, induced expressions of the p62/SQSTM1 gene and protein in AML12
mouse liver cells. Because we previously reported p62/SQSTM1 as a key molecule for antioxidation and cell survival
in hepatocytes, we next examined the activation of nuclear factor erythroid 2-related factor-2 (Nrf2) and induction
of the antioxidant molecules by GW4064. GW4064 activated Nrf2 and subsequently induced antioxidant molecules
(Nrf2, catalase, HO-1, and thioredoxin). We also examined expressions of pro-survival and cell protective molecules
associated with p62/SQSTM1. Expectedly, GW4064 induced phosphorylation of Akt, expression of the anti-apoptotic
molecules (Bcl-xL and Bcl-2), and reduced harmful hepatic molecules (Fas ligand and Fas). GW4064 promoted
hepatocyte survival, which was cancelled by p62/SQSTM1 siRNA. These findings suggest the potential relevance of the
FXR-p62/SQSTM1 pathway for the survival and protection of hepatocytes. Furthermore, GW4064 induced the expression
of small heterodimer partners (SHP) and suppressed liver X receptor (LXR)-induced steatosis in hepatocytes, expecting
the in vivo protective effect of FXR on liver injury especially with steatosis. In the hepatectomy model of db/db mice
with fatty liver, pre-treatment by GW4064 significantly reduced post-PH liver injury (serum levels of LDH, AST & ALT and
histological study) and improved steatosis. The key molecules, p62/SQSTM1, Nrf2 and SHP were upregulated in fatty liver
tissue by GW4064 treatment.
Conclusions: The present study is the first to demonstrate the relevance of FXR-p62/SQSTM1 and -SHP in the protection
against injury of hepatocytes and post-PH liver, especially with steatosis.
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Background
Liver is injured as a result of various physio-pathological
events and sequentially regenerates to quantitatively and
functionally recover from loss of mass and to compen-
sate for impaired function. Liver has the strong ability to
restore lost volume and function, a phenomenon that is
rarely seen in other organs [1, 2]. It is well established
that normal adult hepatocytes usually are quiescent but
have the potential to replicate. After surgical procedures
that reduce liver mass/function and induce liver injury,
such as partial hepatectomy (PH) or live-donor liver
transplantation, a rapid enlargement of the residual or
grafted liver commonly occurs to restore the liver mass
and function [3]. However, post-PH injury of a diseased
liver, for example, in cases of liver cirrhosis or steatosis,
or of aged liver, leads to liver failure and is potentially
fatal [4–7]. Therefore, a better understanding of the mo-
lecular mechanisms of liver injury and protection in
various pathological conditions may lead to clinical
benefits.
Fatty liver is a commonly encountered hepatic disorder
and has various causes, such as obesity, diabetes melli-
tus, and alcohol consumption [7]. It is often considered
a benign condition because it does not usually cause
severe clinical symptoms. However, surgical resection of
fatty liver and live-donor liver transplantation from a
donor with a steatotic liver are problematic because
steatosis often causes the remnant liver failure immedi-
ately and primary graft non-function [7]. Non-alcoholic
steatohepatitis (NASH), has been focused on recently
because its clinical importance has become apparent.
NASH, characterized by persistent inflammation with
mild liver damage, is considered to ultimately result in
liver cancer through liver fibrosis and cirrhosis over
many years [8, 9].
After hepatectomy, various mitotic factors and cyto-
kines promptly activate various cellular signals and
events, eventually leading to sufficient regeneration of
the normal liver [1–3, 10, 11]. In the steatotic liver,
modified signaling mechanisms due to adaptation to
chronic metabolic abnormalities and decreased adeno-
sine triphosphate (ATP) production have been reported
as likely causes of increased mortality and impaired
regeneration after hepatectomy [7, 12, 13]. Very import-
antly, hepatic steatosis is considered to reduce tolerance
to ischemic injury and oxidative stress (OS) [7, 14].
By the way, p62/SQSTM1 is known as a specific sub-
strate for autophagy and therefore has been used as a
marker of autophagy [15, 16]. However, the biological
relevance of p62/SQSTM1 was not understood until
recently other than autophagy [17–22]. We previously
reported that the marked reduction in p62/SQSTM1 in
steatotic hepatocytes is a major cause of post-PH liver
injury and is possibly involved in acute liver failure
following PH [23]. It is known that p62/SQSTM1
directly binds to Keap-1, which inhibits its binding to
nuclear factor erythroid 2-related factor-2 (Nrf2) and
allows Nrf2 to activate/translocate into the nucleus
[18]. Because Nrf2 is a key player in the cellular anti-
oxidant system, it upregulates major antioxidant mol-
ecules and also p62/SQSTM1, and protects cells from
OS. In addition, it was reported that p62/SQSTM1
phosphorylates/activates Akt, a pro-survival molecule
in neuronal cells [21], and reduces the expression of
harmful molecules (Fas ligand; FasL and Fas) in liver
cells [23]. These facts strongly suggest the pro-
survival and anti-cytotoxic effects of p62/SQSTM1 in
liver cells.
Nuclear receptors have been widely studied for their
clinical relevance in various medical fields. In liver, the
farnesoid X receptor (FXR) and liver X receptor (LXR)
are deeply involved in glucose and lipid metabolism,
and, therefore, are considered to play important physio-
pathological roles in homeostasis and survival of living
organisms [24–27]. Regarding FXR, it suppresses the
sterol regulatory element-binding protein (SREBP)-1c
/fatty acid synthase (FAS) pathway through upregulation
of small heterodimer partner (SHP) [24, 25, 27]. The
SHP negatively regulates the SREBP-1c/FAS pathway
and inhibits production of triglycerides (TG) in hepato-
cytes [27]. Therefore, many clinical trials have been per-
formed expecting the therapeutic efficacy of its agonistic
compounds against non-alcoholic fatty liver disease
(NAFLD) such as NASH [28]. Recently, there was evi-
dence that FXR directly upregulates the p62/SQSTM1
gene in hepatocytes [29]. This promptly led us to the
idea that FXR activates the pro-survival signals through
the upregulation of p62/SQSTM1 and, at the same time,
suppresses hepatic steatosis through the upregulation of
SHP. If FXR improves hepatic steatosis as well as heals
the injury in fatty liver or NASH, the signals of FXR-
p62/SQSTM1 may play a pivotal role in maintaining
liver homeostasis and protection against injury especially
of fatty liver.
In this study, we report that FXR stimulus confers the
pro-survival and anti-steatotic properties through induc-
tion of p62/SQSTM1 and SHP to hepatocytes, respect-
ively, and that it suppresses post-PH liver injury
effectively with reduced fat accumulation in a mouse
model. The FXR and p62/SQSTM1-mediated signals of
hepatocytes seem to be relevant in surviving and pro-
tecting hepatocytes in various liver conditions especially
with fatty change.
Methods
Cell culture, reagents, and siRNAs
The alpha mouse liver 12 (AML12) cells, established
from hepatocytes from a mouse transgenic for human
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transforming growth factor-α (TGF-α), express high
levels of human TGFα and lower levels of mouse TGFα
(ATCC, Manassas, VA, USA). AML12 cells were main-
tained at 37 °C in 5.0% CO2 in Dulbecco’s Modified Eagle
Medium: Nutrient Mixture F-12 (DMEM/F12) (Gibco,
CA, USA) supplemented with 10% fetal bovine serum.
GW4064, an agonist of FXR, and T0901317, an agonist
for LXR-α, were purchased from Sigma-Aldrich Co., LLC.
(St. Louis, MO, USA) and Merck Millipore Corporation
(Darmstadt, Germany), respectively. Small interfering
RNAs (siRNAs) for mouse p62/SQSTM1 (sense 5′-GG
AACUCGCUAUAAGUGCATT-3′, antisense 5′-UGCAC
UUAUAGCGAGUUCCCA) and GAPDH used as the con-
trol were purchased from Ambion, Inc. (Austin, TX,
USA). Transfection of siRNAs into AML12 liver cells was
accomplished using Lipofectamine 2000 (Invitrogen,
Rockville, MD, USA) according to the manufacturer’s
instructions. p62/SQSTM1 and GAPDH expressions were
both evaluated by PCR and Western blot analyses.
Reverse transcription-PCR assay
First-strand cDNA synthesis used 2.5 μg of total RNA
from AML12 cells, Superscript III reverse transcriptase,
and oligo(dT)20 primers (Invitrogen, Carlsbad, CA,
USA), according to the manufacturer’s instructions. The
cDNA was amplified by PCR with specific primers for
mouse p62/SQSTM1 (225 bp): sense 5′-GATGTGGAA-
CATGGAGGGAAGAG-3′, antisense 5′-AGTCATCGT
CTCCTCCTGAGCA-3′. PCR was performed by 27 cycles
of denaturation at 94 °C for 30 s, annealing at 55 °C for
30 s, and extension at 72 °C for 30 s.
Monitoring and evaluation of cell survival, cell death and
liver injury
Cells at 40–50% confluence were plated in a plate. Cell
survival was determined by plating the cells in the
xCELLigence System (Roche, Basel, Switzerland), which
allows for automated non-invasive, real-time, and label-
free monitoring of live cells in culture. For evaluation of
cell death, we examined lactate dehydrogenase (LDH)
release from hepatocytes into culture media. “LDH cyto-
toxicity detection kit” (Takara, Otsu, Japan) was used ac-
cording to the manufacturer’s instructions. Briefly, the
LDH reaction mixture was added to the aliquot taken
from the media for cell culture 72 h after the treatment
with GW4064 and incubated at room temperature for
30 min. The absorbance at 490 nm was measured using
a multi-well plate reader. In mouse experiments, bio-
chemical analyses, such as for serum levels of aspartate
aminotransferase (AST), alanine aminotransferase (ALT),
and LDH were performed as indices of liver injury before
and after PH.
Adipogenesis assay
Adipogenesis was evaluated by an “adipogenesis colori-
metric/fluorometric assay kit” (BioVision, Milpitas, CA,
USA) according to the manufacturer’s instructions.
Briefly, cultured cells or liver tissues were harvested,
washed by phosphate buffered saline (PBS), and stored
at −80 °C before the assay. The specimens were com-
pletely dissolved by the lipid extraction buffer provided
by the manufacturer. For the TG assay, 5–50 μl of the
lipid extracts was transferred to a 96-well plate and the
volume was brought to 50 μl with the assay buffer. Spec-
imens and standards were added with 2 μl of lipase,
mixed, and incubated 10 min at room temperature to
convert TG to glycerol and fatty acid. The samples and
standards were mixed with 50 μl of the reaction mix and
measured at 570 nm for the colorimetric assay. Nile red
stain was used to quantify intracellular lipid accumula-
tion in cultured cells. T0901317- and GW4064-treated
AML12 cells were rinsed with PBS and stained with the
lipid-specific Nile red stain (AdipoRed Assay Reagent,
Lonza, Basel, Switzerland). After the incubation at room
temperature for 10 min, cells were applied for the fluor-
escence assay with excitation at 485 nm and emission at
572 nm (expressed as relative fluorescence units, RFU).
Western blot analysis
Western blot analysis was performed with appropriate
antibodies specific for Nrf2 (1:200 dilution), heme
oxygenase-1 (HO-1, 1:500 dilution), manganese-
dependent superoxide dismutase (Mn-SOD, 1:1000 dilu-
tion), thioredoxin (TRX, 1:500 dilution) (BD Transduction
Laboratories, NJ, USA), Bcl-2 (1:200 dilution), Bcl-xL
(1:200 dilution), Fas (1:200 dilution), SHP (1:100 dilution)
(Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA),
FasL (1:200 dilution) (Abcam, Cambridge, UK), catalase
(1:1000 dilution) (EMD Biosciences, Darmstadt,
Germany), p62/SQSTM1 (1:1000 dilution), phospho-Akt
(1:1000 dilution), and Akt (1:1000 dilution) (Cell Signaling
Technology Inc., Danvers, MA, USA) . Whole cell or tis-
sue protein extracts (25 μg) were separated by 10% so-
dium dodecyl sulfate-poly acrylamide gel electrophoresis
(SDS-PAGE) and transferred to a polyvinylidene difluoride
(PVDF) membrane. After blocking in 5% skim milk-PBS
with 1% Tween 20 (PBS-T), the membrane was incubated
in the primary antibody diluted properly (as indicated
above) in PBS-T buffer containing 2% bovine serum albu-
min (BSA) for overnight at 4 °C, and washed 3 times in
PBS-T. The membrane was next incubated with anti-
mouse or anti-rabbit secondary antibody conjugated to
horseradish peroxidase (HRP) (1:5000 dilution) in a block-
ing buffer (5% skim milk in PBS-T) at room temperature
for 1 h. The membrane was finally applied to chemilumin-
escent HRP detection reagent (Luminata Forte Western
HRP substrate, Merck Millipore, Darmstadt, Germany)
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and the chemiluminescent signals were detected using a
CCD imaging system (LuminoGraph, ATTO, Tokyo,
Japan).
Activation assay of Nrf2 in AML12 cells
Activation of Nrf2 in AML12 cells was evaluated by
immunofluorescence microscopic observation. Cells
cultured on a glass bottom dish were stimulated by
GW4064 and then fixed with ice-chilled methanol for
5 min and permeabilized with 0.1% Triton X-100 in PBS
for 10 min at room temperature. After blocking treat-
ment, cells were labeled with anti-Nrf2 as a primary
antibody for 1 h at room temperature, followed by incu-
bation with a secondary antibody conjugated Alexa Fluor
488 (Thermo Fisher Scientific Inc., Waltham, MA,
USA). Then nuclei were counterstained with Hoechst
33342. We investigated the expression and localization
of Nrf2 in AML12 cells with a fluorescent microscope
(Biozero; Keyence Corp., Osaka, Japan).
Animal experiments
Male homozygous leptin receptor-deficient (db/db) mice
(45–50 g body weight, 12 weeks old) were obtained from
CLEA Japan (Tokyo, Japan) and used for the 2/3 PH ex-
periment. GW4064 was administered daily intraperito-
neally (5 mg/kg body weight) for 5 days (3 times before
and 2 times after the surgical procedure). The mice were
fasted overnight prior to the experiments and were anes-
thetized with 1.5–2.0% isoflurane (Forane©, Abbott,
Tokyo, Japan). The laparotomy was performed by mid-
abdominal incision and the median and left liver lobes
were exposed. After ligating the vessels to each liver lobe
with 3–0 braided silk at the base of each lobe, the
median and left liver lobes were surgically resected. The
mice underwent laparotomy after anesthesia, and were
closed without liver lobe ligation and resection for sham
operation. Mice were sacrificed for the collection of liver
specimens at the indicated time points before and after
hepatectomy, and the liver/body weight ratios were
calculated to estimate the recovery of liver mass. The
percentage of the whole liver constituted by each lobe
was similar to the lean mice, and surgical resection of
the middle and left liver lobes resulted in 2/3 PH. Sudan
III stained lipid droplets in more than 90% of the hepa-
tocytes in the liver of db/db mice. The animals were
maintained under standard conditions and treated
according to the Guidelines for the Care and Use of
Laboratory Animals of Hokkaido University.
Histological analysis
Liver tissues were fixed in 10% buffered formalin, paraf-
fin embedded, and subjected to hematoxylin and eosin
staining (H & E). To visualize lipid accumulation in the
liver, frozen sections of formalin-fixed liver tissue were
stained with Sudan III. Briefly, the liver frozen sections
(8 μm thick) were prepared on slide glasses, air-dried
and rinsed with 50% ethanol. Next, the specimens were
stained in Sudan III stain for 10 min at room
temperature, and rinsed again to remove excess stain.
Counterstain (nuclear stain) was performed with
hematoxylin stain for 3 min. After washing gently sev-
eral times by water, the specimens were mounted with
coverslip and microscopically observed.
Statistical analysis
All results were expressed as means ± standard error of
the mean (SEM). Data were compared by Fisher’s test,
and p values of less than 0.05 were considered to be
statistically significant.
Results
GW4064, a specific agonist of FXR, induced p62/SQSTM1
in AML12 liver cells
We first attempted to confirm the expression of p62/
SQSTM1 in AML12 liver cells by FXR stimulus. The
expression of p62/SQSTM1 protein was observed 10 h
after treatment with a specific agonist of FXR, GW4064
(1.0 μM) (Fig. 1a), and continued for at least 36 h. The
protein expression of p62/SQSTM1 at 36 h after the
treatment with GW4064 was observed in a dose-
dependent manner in a range of 0.25 to 2.0 μM (Fig. 1b).
The protein induction of p62/SQSTM1 by GW4064
(1.0 μM) was significantly reduced by siRNA of the p62/
SQSTM1 gene (Fig. 1c). Furthermore, GW4064 induced
the mRNA expression of p62/SQSTM1 in AML12 liver
cells (Fig. 1d).
These data indicate that FXR-agonist upregulates p62/
SQSTM1 gene expression and induces transcriptionally
its protein expression in non-tumorous AML12 liver
cells, supporting the previously reported data that the
p62/SQSTM1 gene is upregulated by FXR in HepG2
cells [29].
An FXR agonist sent signals to anti-oxidant and
pro-survival molecules but not mitosis-associated
molecules in AML12 liver cells
Because FXR induced p62/SQSTM1 in AML12 cells
(Fig. 1), we next studied the effect of the FXR-agonist on
the expression of Nrf2 and its nuclear translocation
(activation), and also the expression of the Nrf2-
associated anti-oxidant molecules in AML12 cells.
Treatment with GW4064 (1.0 μM) induced the rapid
and marked translocation of Nrf2 into nuclei of AML12
liver cells (Fig. 2a). The immunocytochemical study
clearly showed that the nuclear translocation of Nrf2 oc-
curred within 8 h after the treatment with GW4064 and
continued in nuclei at least 36 h. Interestingly, the nu-
clear translocation of Nrf2 was most evident at 1.0 μM
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(Additional file 1), though the protein was expressed
more strongly at 2.0 μM (Fig. 2b). These findings indi-
cate that GW4064 even at lower concentrations rapidly
and persistently induces Nrf2 activation in AML12 liver
cells. As expected, GW4064 induced significant expression
of Nrf2-associated anti-oxidant-associated molecules such
as Nrf2, catalase and HO-1 36 h after the treatment in
AML12 liver cells (Fig. 2b). Mn-SOD and TRX were mildly
induced, but not significantly. Interestingly, HO-1 was in-
duced evidently at the low concentration of GW4064
(0.5 μM), different from other molecules.
Next, we studied the pro-survival effects of FXR on
AML12 liver cells. GW4064 induced the phosphoryl-
ation of Akt (Fig. 2c). GW4064 also induced anti-
apoptotic proteins such as Bcl-xL and Bcl-2 significantly
at 0.5 and 1.0 μM. respectively. The protein expressions
of Fas and FasL, which induce harmful effects on hepa-
tocytes, were also evidently suppressed by GW4064
administration. Though deletion of p62/SQSTM1 clearly
reduced FXR-induced phosphorylation of Akt (T308),
this did not affect the protein expression of the pro-
survival- and apoptosis-associated molecules examined
in this study (Fig. 2d). These facts indicate that these
critical molecules for cell survival and apoptosis are not
only regulated by FXR-p62/SQSTM1 pathway, but also
by the mechanisms other than FXR-p62/SQSTM1.
Regarding cell cycle-associated molecules, the treat-
ment with GW4064 did not affect phosphorylation of
the signal transducer and activator of transcription 3
(STAT3) (Y705) nor protein expressions of cyclinD1 and
proliferating cell nuclear antigen (PCNA) (Fig. 2e).
Activation of the FXR-p62/SQSTM1 pathway improved
liver cell survival
We thereafter studied the effect of the FXR-agonist on
liver cell survival and cell death by monitoring live liver
cells chronologically and LDH release, respectively
(Fig. 3a). We studied the pro-survival effect of GW4064
at concentrations of 0 to 5.0 μM. GW4064 prolonged
cell survival significantly in 0.5–1.0 μM, showing the
peak effects at 1.0 μM. In the same range of concentra-
tions (0.5–2.0 μM), GW4064 reduced mildly but signifi-
cantly LDH release (Fig. 3a). Interestingly, the most
effective concentration of GW4064 for cell survival
(1.0 μM) was almost coincident to that of the protein
expression of p62/SQSTM1 (Fig. 1b). These facts may
Fig. 1 FXR-agonist induced p62/SQSTM1 in AML12 liver cells. a GW4064 (1.0 μM), an FXR-specific agonist, expressed p62/SQSTM1 protein 10 h
after administration and continued at least 36 h in AML12 liver cells. The immunoblot is a representative of the three independent experiments.
b p62/SQSTM1 protein was expressed by GW4064 in a dose-dependent manner (0.25–5.0 μM) at 36 h after the treatment. c The protein induction
of p62/SQSTM1 by GW4064 (1.0 μM) was cancelled by p62/SQSTM1 siRNA (10 nM). d Reverse transcription–PCR analysis of the p62/SQSTM1 gene
in AML12 liver cells. GW4064 robustly upregulated the p62/SQSTM1 gene in 1.0 and 2.0 μM of GW4064. Each blot represents at least three
independent experiments (a, b, c). ImageJ software was used for quantitative analysis of western blot and reverse transcription–PCR. Data
are expressed as mean ± SEM. p values <0.05 were considered statistically significant
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Fig. 2 (See legend on next page.)
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indicate that the pro-survival effect of GW4064 mainly
by protection against cell injury. This effect of GW4064
was significantly reduced by silencing the p62/SQSTM1
gene (Fig. 3b), indicating the possible involvement of
FXR in cell survival/cell protection via FXR-p62/
SQSTM1-associated pathway.
FXR-agonist showed adipogenic and adipolytic effects in
hepatocytes, and protected steatotic hepatocytes from
injury
We studied the expression of SHP by GW4064 at the
same concentrations where GW4064 showed pro-
survival effects in AML12 liver cells (Fig. 4a). Though
SHP was slightly expressed without GW4064 adminis-
tration, its protein expression was upregulated by
GW4064 similarly at 0.5 to 2.0 μM (Fig. 4a). So, we
confirmed whether GW4064 inhibits LXR-induced TG
accumulation in AML12 liver cells.
GW4064 (1.0 μM and 5.0 μM), when concurrently
administered with T0901317 (an LXR-agonist), effect-
ively suppressed TG accumulation in hepatocytes
(Fig. 4b). We also examined whether or not GW4064
reduces the accumulated TG in hepatocytes after the
treatment with T0901317 (Fig. 4c). GW4064 reduced
TG content of AML12 liver cells dose-dependently,
showing the adipolytic effect on steatotic hepatocytes.
In the steatotic hepatocytes, GW4064 reduced mildly
but significantly LDH release from steatotic hepato-
cytes (cell protective effect). Though the protective ef-
fect of hepatocytes by GW4064 was not great, it
showed evident adipolytic effect in the steatotic
(See figure on previous page.)
Fig. 2 FXR-agonist activated Nrf2 and induced the expressions of Nrf2 & anti-oxidant molecules in AML12 cells. a Nrf2 in cytosols was translocated
into nuclei by GW4064 treatment (1.0 μM) in AML12 cells. Nrf2 was not stained in nuclei without GW4064 (arrowheads), but clearly stained in nuclei
8 h after GW4064 administration (arrows). 4′ 6-diamidino-2-phenylindole dihydrochloride (DAPI) was used for nuclear stain in blue (pseudo-colored red).
Scale bar, 50 μm b The protein expression of Nrf2 and the antioxidant molecules (catalase, heme oxygenase-1; HO-1, manganese-
dependent superoxide dismutase; MnSOD, and thioredoxin; TRX) 36 h after the treatment with GW4064 (1.0 μM). c GW4064 induced
phosphorylation of Akt and anti-apoptotic molecules (Bcl-xL and Bcl-2), and suppressed the expressions of harmful hepatic molecules such
as FasL and Fas in AML12 liver cells. d Ablation of GW4064 by p62/SQSTM1 siRNA reduced phosphorylation of Akt, which was induced by
GW4064 in AML12 liver cells, though this does not affect the protein expressions of the other molecules. e GW4064 did not affect cell
cycle-associated molecules. GW4064 did not phosphorylate STAT3 (Y705) nor induce cyclinD1 and PCNA. Each experiment was performed
three times and representative photographs are shown. The duplicates of immunoblots are taken from the specimens of experiments performed
at different times. ImageJ software was used for quantitative analysis of western blot. The quantitative analysis data are expressed as mean ± SEM.
p values <0.05 were considered statistically significant (*: p < 0.05 vs GW-0 μM group; **: p < 0.05 vs GAPDH siRNA & GW-1.0 μM group)
Fig. 3 FXR-agonist improved cell survival through p62/SQSTM1 in AML12 liver cells. a GW4064 improved cell survival significantly at 0.5, 1.0 and
5.0 μM, showing the peak effect at 1.0 μM. (*: p < 0.05 vs non-stimulant group) GW4064 significantly suppressed LDH release 72 h after the treatment
at 0.5, 1.0 and 5.0 μM. (**: p < 0.05 vs GW-0 μM group) b Cell survival effects of GW4064 was cancelled partially but significantly by p62/
SQSTM1 knockdown (10nM of siRNA of p62/SQSTM1 gene). (* : p < 0.05 vs no siRNA group; **: p < 0.05 vs no siRNA & GAPDH siRNA
groups) Each experimental group consisted of at least three independent experiments. Data are expressed as mean ± SEM. p values <0.05
were considered statistically significant
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hepatocytes. These facts led us to expect the in vivo
effect in a mouse model with fatty liver.
LXR-agonist improved post-PH liver injury and steatosis
in db/db mice
Lastly, we examined in vivo effects of FXR by using a
mouse PH model with fatty liver. We studied whether a
FXR-agonist suppresses post-PH liver injury, improves
steatosis and recovery in the db/db mouse. To study the
injury of steatotic liver, we evaluated biochemical
markers (serum levels of LDH, AST, and ALT) and
histological changes. A significant improvement in liver
injury was observed in the GW4064-treated mice 72 h
post-PH (Fig. 5a and b). The biochemical markers in
both groups (GW4064-untreated and -treated groups)
similarly increased immediately after PH (24 h post-PH),
possibly due to the direct mechanical injury to the liver
by surgical maneuver. However, an improvement in the
biochemical markers was observed in the GW4064-
treated mice 72 h post-PH (Fig. 5a). Histological examin-
ation also supported the blood biochemistry data,
showing that detachment of endothelial cells of central
veins (arrowheads in black) and spotty cellular necrosis
and hemorrhage (arrowheads in white) were observed
mainly in the liver of non-treated db/db mice, but not in
the liver of the GW4064-treated mice (Fig. 5b). The mi-
totic hepatocytes were not particularly observed both in
GW4064-treated and non-treated livers. These data and
observations indicate that the treatment with GW4064
(5 mg/kg BW) suppressed post-PH liver injury, but did
not affect mitotic response. Histological examination (H
& E and Sudan III stains) also revealed that lipid accu-
mulation in liver was obviously lower pre- and post-PH
in the GW4064-treated mice (Fig. 5b and c). Biochem-
ical analysis of TG contents in liver tissue also showed
reduction tendency of TG in the livers of GW4064-
treated mice (Fig. 5c), though the difference was not sta-
tistically significant. Serum levels of glucose and TG
after PH were not affected by GW4064 treatment
(Additional file 2).
Western blot analysis revealed that GW4064 induced
p62/SQSTM1, Nrf2 and SHP significantly after PH
(Fig. 5d). SHP protein was induced even before PH (pre-
operative 3 day-administration of GW4064, 5 mg/kg)
continued until 72 h post-PH. Post-PH liver mass recov-
ery was improved slightly 24 h post-PH and more 72 h
Fig. 4 FXR-agonist induced expression of SHP, showed adipogenic and adipolytic effects in hepatocytes, and protected steatotic hepatocytes.
a Expression of SHP was induced by GW4064 (0.5 to 2.0 μM) 36 h after the treatment in AML12 liver cells. Each blot represents at least three
independent experiments. The duplicates of immunoblots are taken from the specimens of experiments performed at different times. ImageJ
software was used for quantitative analysis of western blot. b Steatosis was observed in AML12 liver cells by treatment with 1.0 and 5.0 μM of
T0901317 (a specific agonist of LXR) for 7 days. The accumulation of TG induced by T0901317 was significantly suppressed by the concurrently
administered GW4064 (1.0 μM). c The adipolytic and protective effects of GW4064 were evaluated by using LXR-induced steatotic hepatocytes.
The treatment with T0901317 robustly reduced TG contents in a dose-dependent manner, and reduced cell death (LDH release) of the steatotic
hepatocytes. Each experiment was performed three times and the data are expressed as mean ± SEM. p values of <0.05 were considered
statistically significant
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post-PH by GW4064 treatment, but the difference was
not statistically significant (Fig. 5e).
Discussion
Recently, p62/SQSTM1 has been considered to play
major roles in the protection from injury in various
organs and pathological conditions, independent of
autophagy [18–23]. In liver, we previously demonstrated
that steatosis induced the reduction of p62/SQSTM1 in
hepatocytes, which causes post-PH necrotic and apop-
totic acute liver injury by enhancing OS and the FasL/
Fas signaling pathway [23]. p62/SQSTM1 positively
regulated the DNA binding activity of Nrf2 by physical
association with Keap-1 and activates its transcriptional
activity on ARE. Therefore, reduction of p62/SQSTM1
in hepatocytes, regardless of the existence of steatosis,
Fig. 5 FXR-agonist improved post-PH liver injury and steatosis in db/db mice. a Blood biochemistry data are shown. Serum levels of LDH, AST
and ALT were reduced 72 h post-PH by the treatment with GW4064 (5 mg/kg BW, refer to Materials and Methods for details). b Hematoxylin and
eosin (H & E) staining of liver tissue. Upper panel: The droplets of hepatocytes were obviously reduced in the GW4064-treated mice before PH.
Lower panel: The detachment of endothelial cells (arrowhead in black) and spotty necrosis with hemorrhage (arrowheads in white) observed 72 h
post-PH in control mice were not notable in the GW4064-treated mice. c Sudan III staining of liver tissue revealed that steatotic hepatocytes were
obviously reduced in the GW4064-treated mice without PH. The content of TG was reduced in the liver treated with GW4064, but not statistically
significant. d Western blot analysis revealed the increased expression of p62/SQSTM1, Nrf2 and SHP in the liver tissue of the GW4064-treated mice.
Each blot represents at least three independent experiments. The duplicates of immunoblots are taken from the specimens of experiments performed
at different times. ImageJ software was used for quantitative analysis of western blot. e Post-PH liver mass recovery was slightly improved in the
GW4064-treated mice, but the difference was not statistically significant. At least four mice were used for each experiment and the representative data
are shown (a, b, c, e). The data are expressed as mean ± SEM (a, c, d, e). p values <0.05 were considered statistically significant
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lowered the expression of anti-oxidant molecules (cata-
lase, MnSOD, Ref-1, HO-1, TRX, and GPx) by increas-
ing Keap-1/Nrf2 binding (i.e., decreasing ARE activity),
making the hepatocytes/liver susceptible to harmful OS.
The increases in FasL and Fas by reduced p62/SQSTM1
led to caspase-mediated apoptosis and OS-mediated
necrosis in steatotic hepatocytes/liver. These mecha-
nisms were likely to be a main cause of post-PH fatty
liver injury. On the contrary, overexpression of p62/
SQSTM1 by gene transduction increased the expressions
of anti-oxidant molecules through activation of the Nrf2
pathway and also reduced harmful hepatic molecules
such as FasL and Fas in hepatocytes and liver. Therefore,
upregulation of p62/SQSTM1 seems to be a good clin-
ical target for liver protection, especially against fatty
liver and NASH where OS and FasL/Fas undoubtedly
contribute to fatty liver injury [23].
By the way, FXR is a member of the nuclear receptor
superfamily and is a ligand-activated transcription factor
that is essential for maintaining mainly hepato-intestinal
homeostasis [24, 25]. FXR has the effects against car-
cinogenesis and inflammation in liver and intestine as
demonstrated by the development of inflammation and
tumors of FXR knock-out mice [29]. However, the
mechanisms of the physio-pathological effects of FXR
are not completely understood. Recently, a novel target
gene of FXR was identified in the regulation of p62/
SQSTM1 gene expression [29]. The anti-adipogenic
effect of FXR also has been reported in hepatocytes [30].
FXR therefore has been a potent therapeutic target
against NAFLD including NASH [28]. It is known that
FXR upregulates SHP, which suppresses LXR/SREBP-1c/
FAS-mediated production of TG in hepatocytes [27].
This promptly led us to the idea that upregulation of
liver-protective p62/SQSTM1 by FXR may provide liver-
specific protection against oxidative and Fas-mediated
injuries. FXR-p62/SQSTM1 may send “protective sig-
nals” to steatotic hepatocytes and fatty liver which are
vulnerable to oxidative stress and Fas-mediated death
signals. Here in the present study, the treatment with
GW4064 reduced TG contents in hepatocytes presum-
ably by suppressing adipogenesis and promoting adipoly-
sis (Fig. 4b and c). FXR suppressed accumulation of TG
in AML12 cells possibly by reducing its cellular produc-
tion through upregulating SHP and inhibiting the
SREBP-1c/FAS pathway. Regarding adipolysis by LXR,
further study has to be performed to confirm this result
and elucidate the underlying mechanism. Though the
treatment with FXR slightly lowered hepatic TG con-
tents in db/db mice, the defatting effect of FXR was not
evident in vivo. Because the model mice used in this
study were diabetic with severe fatty liver (Fig. 5c), they
might have been too extreme to evaluate correctly the
effect of GW4064. In order to confirm the anti-
adipogenic and/or adipolytic effects of FXR on liver stea-
tosis, we must perform additional experiments by using
the other physio-pathological mouse models. However,
these properties of FXR indicate the potent contribution
to the protection against fatty and even non-fatty livers
from surgical stress and/or injury and to improve steato-
sis via p62/SQSTM1 and SHP in various clinical settings
(Fig. 6).
Regarding the pro-survival and cell protective effects
by FXR in hepatocytes, FXR-agonist showed mild but
certain pro-survival and protective effects via p62/
SQSTM1 in non-healthy steatotic hepatocytes as well as
healthy hepatocytes (Figs. 3 and 4c), indicating the
potent protective effect in various physio-pathological
conditions of liver and intestine cells. These effects were
confirmed by using the mouse surgical model with fatty
liver. Post-PH liver injury was significantly improved by
the treatment with LXR-agonist (Fig. 5a, b). Unfortu-
nately, it failed to induce post-PH mitotic response
(hepatocyte proliferation) and to regenerate the remnant
liver significantly. The failure to promote post-PH
mitotic response and regeneration may be explained by
the negative effects of GW4064 on mitosis-associated
proteins (Fig. 2e).
Whereas, Huang, W. et al. [31] and Xie, Y. et al. [32]
reported the potential effects of FXR on hepatocyte
proliferation in vitro and in vivo. FXR stimulated mitotic
response in the post-PH mouse liver [31] and
acetaminophen-treated mouse liver [32]. Regarding the
in vitro experiments, Xie, Y. et al. used human cancer
cell line (HepG2) which possesses autonomic prolifera-
tive capability, and we differently used AML12 cells in
the present study, which were maintained by TGF-α
secreted in autocrine/paracrine fashions. They studied
Fig. 6 Schematic illustration of a crucial role of FXR-p62/SQSTM1
pathway in liver/hepatocyte protection. FXR upregulates Nrf2-
regulated antioxidants, activates (phosphorylates) pro-survival Akt
and suppresses harmful FasL/Fas via p62/SQSTM1, and therefore
protects against liver/hepatocyte injury. FXR also improves steatosis
of hepatocytes/liver possibly by suppressing LXR/SREBP-1c/FAS
adipogenic pathway via SHP. FXR may be one of the key molecules
in protecting steatotic hepatocyte/liver injury
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MTT assay for evaluation of live cells and BrdU in-
corporation for proliferation in HepG2 cells. The live
cell numbers and BrdU incorporation of HepG2 cells
were certainly increased by the treatment with
GW4064 (1.0–5.0 μM). In the paper, they concluded
that FXR may promote proliferation of HepG2 tumor
cells by activating pyruvate dehydrogenate kinse4
(PDK4)-mediated metabolic reprogramming and gen-
erating glycolytic intermediates required for cell
proliferation, which was not observed in healthy he-
patocytes. This indicates that FXR-stimulus may pro-
mote cell proliferation, but not be a sufficient
condition for non-tumorous cells. The enhancement
of proliferation by GW4064 may require basically the
autonomic proliferative capability of cells (such as
HepG2 cells). Taken together, we think that the hepa-
tocytes with autonomic/strong proliferative capability
can be stimulated with some kinds of trigger such as
“metabolic switch”, whereas that of healthy hepato-
cytes whose proliferation is not driven autonomically/
strongly cannot be stimulated by the metabolic
changes alone. Similar to FXR, the association of p62/
SQSTM1 with tumor have been reported [30, 33].
The anti-oxidant and pro-survival properties of p62/
SQSTM1, is surely expected to prevent oxidative
stress, cell death (injury) and inflammation in normal
hepatocytes/liver. However, p62/SQSTM1, if accumu-
lated excessively in cells, may contribute to oncogen-
esis, especially in liver.
These complicated mechanisms in FXR- and p62/
SQSTM1-associated physio-pathology make it difficult
to understand its role in various conditions. There-
fore, it seems to be a limitation for interpretation of
the physio-pathological roles of FXR and p62/
SQSTM1 in the present study. In order to evaluate
properly the proliferative/pro-survival and the other
effects of FXR on liver physio-pathology, we must
perform additional experiments using other ligands
with various concentrations in healthy and non-
healthy hepatocytes, and also confirm by using the
other physio-pathological models.
Conclusions
This study is the first to show the critical roles of the
FXR-p62/SQSTM1 pathway in the protection against
post-PH liver injury and possibly the FXR-SHP path-
way in the improvement of liver steatosis. Further
studies are required to elucidate thoroughly the
mechanisms of protection against injury in steatotic
and non-steatotic liver. However, the present data
provide important clues toward the development of
new therapies specifically against liver injury without
affecting other organs/tissues.
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